Novartis Q1 Profit Falls Short of Market Estimates
The Swiss drugmaker reported a core operating profit of 4.9 billion dollars for the first quarter. This figure fell below analyst expectations of 5.1 billion.
Xurve View
Insights:
Xurve View
The pharmaceutical giant NOVARTIS AG-REG reported its first-quarter financial results on Tuesday, revealing a core operating profit that fell short of market expectations. The company, headquartered in Switzerland, attributed the performance gap largely to the impact of generic competition in the United States targeting its primary revenue driver.
